Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$10.58 USD
-0.07 (-0.66%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $10.57 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.58 USD
-0.07 (-0.66%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $10.57 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Will Avid Bioservices (CDMO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 25.00% and 23.74%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for November 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for October 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Why Avid Bioservices (CDMO) Could Be Positioned for a Slump
by Zacks Equity Research
Avid Bioservices (CDMO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Avid Bioservices (CDMO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of -166.67% and 5.56%, respectively, for the quarter ended July 2019. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 28.57% and 2.65%, respectively, for the quarter ended January 2019. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and -5.32%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Avid Bioservices (CDMO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options
by Zacks Equity Research
Avid Bioservices (CDMO) needs investors to pay close attention to the stock based on moves in the options market lately.
Avid Bioservices (CDMO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 26.52%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Q1 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avid Bioservices, Mellanox, Berkshire Hathaway, Intel and Chevron highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Avid Bioservices, Mellanox, Berkshire Hathaway, Intel and Chevron highlighted as Zacks Bull and Bear of the Day
Avid Bioservices (CDMO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 6.67% and 6.65%, respectively, for the quarter ended April 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Avid Bioservices (CDMO) Stock
by Zacks Equity Research
Avid Bioservices (CDMO) needs investors to pay close attention to the stock based on moves in the options market lately.